Table 3.

Studies on the use of paromomycin.

Study	Population	Size	Disease severity	Regimen	Comparison	Follow up period	Clinical improvementa	Parasite clearanceb
Fichtenbaum et al. (1993)	30-49 yo with HIV	7	All intensity	500 mg QID for 10–14 days	None	Weekly up to 6 months	100%	75% (3/4)
Bissuel et al. (1994)	25-62 yo with HIV	24	All intensity	1 g BID for 4 weeks, 500 mg BID for maintenance	None	N/A, 3 stool samples	92% (21/24)	92% (21/24)
Flanigan et al. (1996)	Adults with HIV (CD4 ≤200 cells/uL)	44	All intensity	500 mg QID for 4 weeks	None	Weeks 2 and 4	48% (21/44)	46% (12/26)
Smith et al. (1998)	23-44 yo with HIV (CD4 <100 cells/uL)	11	Chronic cryptosporidiosis	1 g paromomycin BID for 8 weeks plus 600 mg azithromycin OD for 8 weeks	None	Weeks 2, 4 and 12	27% (3/11)	60% (6/10)
White et al. (1994)	25-38 yo with HIV (CD4 <100 cells/uL)	10	Chronic cryptosporidiosis	500 mg TID or QID for 14 days	Placebo	Weekly during therapy	50% (3/6) vs. 0	67% (4/6) vs. 0
Hewitt et al. (2000)	≥13 yo with HIV (CD4 ≤150 cells/uL)	31	All intensity	500 mg QID for 21 days	Placebo	Weeks 1, 3, 4, 6, and 9	47% (8/17) vs. 36% (5/14)b	35% (6/17) vs. 29% (4/14)b
Hussien et al. (2013)	6 mo to 10 yo with malnutrition	135	All intensity	25 mg/kg/d For 14 days	Nitazoxanide 100–200 mg BID for 3 days	At the end of treatment	69% (31/45) vs. 87% (39/45)a	69% (31/45) vs. 87% (39/45)a

^aP < 0.05.

^bNot statistically significant.

NS: not statistically significant.

^aEither abatement of diarrhea or reduced stool frequency or volume.

^bEither complete eradication or reduction of oocyst number.